Dihex (CAS 1401708-83-5) – Selective SGLT2 Inhibitor Antidiabetic & Weight Loss API

Dihex (CAS 1401708-83-5) is a high-purity pharmaceutical API classified as a selective SGLT2 inhibitor, featuring a novel glucoside-derived molecular structure engineered for targeted metabolic regulation. It acts by inhibiting sodium-glucose cotransporter 2 in the renal proximal tubule, blocking glucose reabsorption and promoting urinary glucose excretion—effectively lowering blood glucose levels without increasing insulin secretion. This unique mechanism also induces mild diuresis and calorie loss, delivering synergistic weight reduction benefits for patients with type 2 diabetes and obesity.

With high selectivity for SGLT2 over SGLT1, it minimizes gastrointestinal side effects, ensuring excellent tolerability for long-term use. It caters to the core needs of metabolic drug manufacturers, antidiabetic formulation developers, and weight management therapy suppliers. Widely applied in developing treatments for type 2 diabetes mellitus (T2DM) and obesity-related metabolic disorders, it aligns with demand for dual-action, cardiorenal protective metabolic therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and stability testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use.